MedTrace Logo

Niraparib + Dostarlimab + RT in Pancreatic Cancer

NCT04409002 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-08-15

Study results available
· View outcomes & findings →

Summary

This research is being done to see how the combination of dostarlimab, niraparib, and radiation therapy works in controlling metastatic pancreatic cancer.

Conditions

Interventions

DRUG

Niraparib

Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment

DRUG

Dostarlimab

Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study

RADIATION

Radiation

Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1

Sponsors & Collaborators

  • Tesaro, Inc.

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Julie L Koenig, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-23
Primary Completion
2022-01-19
Completion
2022-02-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04409002 on ClinicalTrials.gov